Testimony, Briefings, Statements, & Reports
Statement of Dr. Diana Zuckerman, Yasmin, Yaz and Other Drospirenone Birth Control Products, December 8th, 2011
Dr. Diana Zuckerman spoke at the December 8, 2011 FDA meeting on the safety of Bayer’s birth control pills Yasmin and Yaz and other drospirenone birth control products, advocating for these high risk drugs to be taken off the market. Read More
Statement of Dr. Diana Zuckerman, PhD regarding the Senate Aging Committee Hearing on Atypical Antipsychotic Drugs, November 30, 2011
November 30, 2011. Dr. Diana Zuckerman, the president of NRC, provided a statement for the Senate Aging Committees regarding problems with antipsychotic drugs.
Read More
Statement of Dr. Diana Zuckerman,PhD, at the Public Meeting on Prescription Drug User Fee Act (PDUFA) Reauthorization, October 24, 2011
Diana Zuckerman,Ph.D, president of the National Research Center for Women & Families testifies at a public hearing on the Prescription Drug User Fee Act. Read More
Testimony of Dana M. Casciotti, MPH, PhD, at the FDA advisory committee meeting on breast implants, August 31, 2011
Dana Casciotti, the public health research director of NRC testifies at an FDA advisory meeting on breast implants. Read More
Dr. Diana Zuckerman, testimony at FDA advisory meeting on breast implants
NRC President, Dr. Diana Zuckerman testifies at an FDA advisory hearing on breast implants. Read More
Testimony of Dr. Diana Zuckerman at the FDA Obstetrics & Gynecology Devices Advisory Panel September 9, 2011
We agree with the FDA that serious adverse events from mesh are NOT rare. No man or woman wants to suffer from incontinence, but there is no doubt that the terribly painful complications can be much worse than the incontinence that initially led to surgery. And, those complications are often impossible to repair. Read More
Brandel France de Bravo,MPH, Director of Public Affairs and Communications, before the FDA, September 8, 2011
September 8, 2011. National Research Center of Women & Families Brandel France de Bravo testifies at the FDA meeting on pelvic mesh. Read More
Statement of Diana Zuckerman, PhD Before the FDA Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risks Management Advisory Committee September 9, 2011
September 9, 2011. NRC president Diana Zuckerman testifies before the FDA Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risks Management Advisory Committee Read More
Testimony of Diana Zuckerman, PhD, President of the Cancer Prevention and Treatment Fund, Before the FDA, September 8, 2011
September 8, 2011. National Research Center of Women & Families President Diana Zuckerman testifies at the FDA meeting on pelvic mesh. Read More
Report: Medical Devices Lack Evidence of Safety and Effectiveness
July 29, 2011. The prestigious Institute of Medicine (IOM) released a report on the Food and Drug Administration’s 510(k) medical device clearance process stating the system is “flawed” and should be revised. The report echoes the National Research Center for Women & Families’ concerns about the lack of evidence that these devises actually work and are safe. Read More